The remaining nearly 600 people were randomized to receive tirzepatide or a placebo via weekly injections for about 16 months
Lisa Otero, APRN, FNP-C brings nearly two decades of nursing and surgical experience to her aesthetic practice in Lake Mary and Winter Park
Diabetes (20192020) 6869(2):2678
Start your intake How Tirzepatide and Semaglutide Work Differently Semaglutide is a GLP-1 receptor agonist, meaning it activates one specific hormone pathway in your body to reduce appetite and improve blood sugar control
population, and many of these individuals also struggle with weight management
A 2025 pooled analysis showed meaningful weight loss across all menopause stages: Pre-menopausal women: 18.2% average weight loss Peri-menopausal women: 15.0% average weight loss Post-menopausal women: 15.7% average weight loss The hormonal changes of perimenopause declining estrogen, increasing insulin resistance, redistribution of fat toward the abdomen are often precisely what makes weight management feel impossible during midlife